

# Marc S Rendell

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1043356/marc-s-rendell-publications-by-citations.pdf>  
**Version:** 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63 papers	2,393 citations	23 h-index	48 g-index
64 ext. papers	2,679 ext. citations	6.4 avg, IF	5.03 L-index

#	Paper	IF	Citations
63	Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. <i>Clinical Therapeutics</i> , <b>2000</b> , 22, 1395-409	3.5	314
62	Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: A randomized controlled trial. rhNGF Clinical Investigator Group. <i>JAMA - Journal of the American Medical Association</i> , <b>2000</b> , 284, 2215-21	27.4	266
61	A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. <i>Diabetes Care</i> , <b>2002</b> , 25, 2058-64	14.6	233
60	The role of sulphonylureas in the management of type 2 diabetes mellitus. <i>Drugs</i> , <b>2004</b> , 64, 1339-58	12.1	216
59	Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study. <i>American Journal of Medicine</i> , <b>2001</b> , 111, 10-7	2.4	207
58	Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. <i>Diabetes Care</i> , <b>2015</b> , 38, 1181-8	14.6	138
57	Manifestations of cutaneous diabetic microangiopathy. <i>American Journal of Clinical Dermatology</i> , <b>2005</b> , 6, 225-37	7.1	72
56	Diabetic cutaneous microangiopathy. <i>American Journal of Medicine</i> , <b>1992</b> , 93, 611-8	2.4	70
55	Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise. <i>Diabetologia</i> , <b>2016</b> , 59, 266-74	10.3	64
54	Targeting postprandial hyperglycemia. <i>Metabolism: Clinical and Experimental</i> , <b>2006</b> , 55, 1263-81	12.7	62
53	What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. <i>Annals of Internal Medicine</i> , <b>2012</b> , 157, 137-8	8	54
52	C-peptide levels as a criterion in treatment of maturity-onset diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>1983</b> , 57, 1198-206	5.6	44
51	Skin blood flow in diabetic dermopathy. <i>Archives of Dermatology</i> , <b>2004</b> , 140, 1248-50		38
50	DPP-4 inhibitors: focus on safety. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 127-40	4.1	34
49	The relationship of laser-Doppler skin blood flow measurements to the cutaneous microvascular anatomy. <i>Microvascular Research</i> , <b>1998</b> , 55, 3-13	3.7	34
48	Screening for familial and hereditary prostate cancer. <i>International Journal of Cancer</i> , <b>2016</b> , 138, 2579-91	17.5	33
47	Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , <b>2015</b> , 6, 109-34	4.5	33

46	Insulin Glargine: a review 8 years after its introduction. <i>Expert Opinion on Pharmacotherapy</i> , <b>2009</b> , 10, 705-18	4	33
45	The skin blood flow response in wound healing. <i>Microvascular Research</i> , <b>1997</b> , 53, 222-34	3.7	32
44	Alogliptin: a new addition to the class of DPP-4 inhibitors. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2009</b> , Volume 2, 117-126	3.4	29
43	Combination therapy with pioglitazone plus metformin or sulfonylurea in patients with Type 2 diabetes: influence of prior antidiabetic drug regimen. <i>Journal of Diabetes and Its Complications</i> , <b>2003</b> , 17, 211-7	3.2	27
42	The Importance of Understanding the Stages of COVID-19 in Treatment and Trials. <i>AIDS Reviews</i> , <b>2021</b> , 23, 40-47	1.5	23
41	Pharmacotherapy of type 2 diabetes mellitus. <i>Annals of Pharmacotherapy</i> , <b>2000</b> , 34, 878-95	2.9	21
40	Skin blood flow in the Wistar-Kyoto rat and the spontaneously hypertensive rat. <i>Comparative Biochemistry and Physiology A, Comparative Physiology</i> , <b>1993</b> , 106, 349-54		19
39	A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs. <i>Drugs</i> , <b>2013</b> , 73, 1025-54	12.1	18
38	Alogliptin benzoate for the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 553-63	4	17
37	Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials. <i>Diabetes Research and Clinical Practice</i> , <b>2017</b> , 126, 230-239	7.4	16
36	Three-year data from 5 HARMONY phase 3 clinical trials of albiglutide in type 2 diabetes mellitus: Long-term efficacy with or without rescue therapy. <i>Diabetes Research and Clinical Practice</i> , <b>2017</b> , 131, 49-60	7.4	16
35	Ischemic and pressure-induced hyperemia: a comparison. <i>Archives of Physical Medicine and Rehabilitation</i> , <b>1998</b> , 79, 1451-5	2.8	14
34	Cilostazol treatment of claudication in diabetic patients. <i>Current Medical Research and Opinion</i> , <b>2002</b> , 18, 479-87	2.5	14
33	The microvascular composition of the healing wound compared at skin sites with nutritive versus arteriovenous perfusion. <i>Journal of Surgical Research</i> , <b>1998</b> , 80, 373-9	2.5	13
32	The Health Care Status of the Diabetic Population as Reflected by Physician Claims to a Major Insurer. <i>Archives of Internal Medicine</i> , <b>1993</b> , 153, 1360		13
31	Skin blood flow abnormalities in diabetic dermopathy. <i>Journal of the American Academy of Dermatology</i> , <b>2011</b> , 65, 559-563	4.5	12
30	The path to approval of new drugs for diabetes. <i>Expert Opinion on Drug Safety</i> , <b>2013</b> , 12, 195-207	4.1	11
29	Glargine safety, diabetes and cancer. <i>Expert Opinion on Drug Safety</i> , <b>2013</b> , 12, 247-63	4.1	11

28	Albiglutide: a unique GLP-1 receptor agonist. <i>Expert Opinion on Biological Therapy</i> , <b>2016</b> , 16, 1557-1569	5.4	11
27	Endogenous Insulin Secretion Measured by C-peptide in Maturity-Onset Diabetes Controllable by Diet Alone. <i>Archives of Internal Medicine</i> , <b>1981</b> , 141, 1617		10
26	Long-Term Performance of Point-of-Care Hemoglobin A1c Assays. <i>Journal of Diabetes Science and Technology</i> , <b>2016</b> , 10, 1308-1315	4.1	10
25	Cutaneous blood flow and peripheral resistance in type II diabetes as compared to intermittent claudication patients. <i>International Journal of Angiology</i> , <b>2003</b> , 12, 166-171	1.1	9
24	The time to offer treatments for COVID-19. <i>Expert Opinion on Investigational Drugs</i> , <b>2021</b> , 30, 505-518	5.9	9
23	Skin blood flow response in the rat model of wound healing: expression of vasoactive factors. <i>Journal of Surgical Research</i> , <b>2002</b> , 107, 18-26	2.5	7
22	Albiglutide for the management of type 2 diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2018</b> , 13, 1-8	4.1	6
21	The journey from gene knockout to clinical medicine: telotristat and sotagliflozin. <i>Drug Design, Development and Therapy</i> , <b>2019</b> , 13, 817-824	4.4	5
20	A 21 CFR Part 11 compliant graphically based electronic system for clinical research documentation. <i>Journal of Medical Systems</i> , <b>2012</b> , 36, 1661-72	5.1	5
19	Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. <i>Postgraduate Medicine</i> , <b>2011</b> , 123, 183-6	3.7	5
18	Efficacy and safety of sotagliflozin in treating diabetes type 1. <i>Expert Opinion on Pharmacotherapy</i> , <b>2018</b> , 19, 307-315	4	5
17	Sotagliflozin: a combined SGLT1/SGLT2 inhibitor to treat diabetes. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2018</b> , 13, 333-339	4.1	5
16	Commentary on Almassalha et al., "The Greater Genomic Landscape: The Heterogeneous Evolution of Cancer". <i>Cancer Research</i> , <b>2016</b> , 76, 5602-5604	10.1	4
15	The future of inpatient diabetes management: glucose as the sixth vital sign. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2013</b> , 8, 195-205	4.1	4
14	The safety of albiglutide for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 1089-1097	4.1	4
13	The effect of polycythemia on skin blood flow in hypertensive rats. <i>Comparative Biochemistry and Physiology A, Comparative Physiology</i> , <b>1995</b> , 112, 355-363		4
12	Premix insulins in type 1 diabetes: the coming of degludec/aspart. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2019</b> , 15, 341-348	5.5	3
11	Insulin: moments in history. <i>Drug Development Research</i> , <b>2008</b> , 69, 95-100	5.1	3

10	United States experience of insulin degludec alone or in combination for type 1 and type 2 diabetes. <i>Drug Design, Development and Therapy</i> , <b>2017</b> , 11, 1209-1220	4.4	2
9	The effect of vasoactive agents on post-pressure hyperemia. <i>Microvascular Research</i> , <b>2012</b> , 84, 345-50	3.7	2
8	THE TIME COURSE OF THERAPEUTIC INTERVENTIONS FOR COVID-19		2
7	Commentary: SGLT inhibitors in type 1 diabetes: Place in therapy and a risk mitigation strategy for preventing diabetic ketoacidosis - the STOP DKA protocol. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 2189-2191	6.7	1
6	The time to develop treatments for diabetic neuropathy. <i>Expert Opinion on Investigational Drugs</i> , <b>2021</b> , 30, 119-130	5.9	1
5	Current and emerging gluconeogenesis inhibitors for the treatment of Type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 2167-2179	4	1
4	Pharmacotherapeutic options for prediabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 45-54	4	0
3	Insulin treatment of post-prandial hyperglycemia. <i>Drug Development Research</i> , <b>2008</b> , 69, 124-129	5.1	
2	Postprandial hyperglycemia: Why do we care about it? What should we do?. <i>Drug Development Research</i> , <b>2006</b> , 67, 582-586	5.1	
1	Report on the 2nd Annual Metabolic Diseases World Summit. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2006</b> , 1, 467-468	4.1	